The Multiple Sclerosis Society of Canada has awarded CA$1 million to a project helping doctors who treat multiple sclerosis (MS) patients make more personalized treatment decisions through the use of artificial intelligence (AI). The society awarded the five-year grant (worth about $814,800) to Douglas Arnold, MD, a neurologist with…
AI
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17–22. Go here to read stories from the conference. After starting treatment with the multiple sclerosis (MS) therapy Mavenclad (cladribine), some types of immune cells are more affected…
Using artificial intelligence (AI) on imaging data collected from multiple sclerosis (MS) patients, researchers were able to classify these people into three new disease subtypes, each distinct from the current groupings determined by symptoms. These new subtypes may allow doctors to better determine those patients more likely to have…
A machine learning-based method that examines walking abnormalities in people with multiple sclerosis (MS) could help identify patients who are at high risk of worsening symptoms, a study suggests. The study, “Predicting Multiple Sclerosis from Gait Dynamics Using an Instrumented Treadmill – A Machine Learning Approach,”…
BioLiberty, a Scottish biotech startup, has developed a robotic glove that uses artificial intelligence (AI) to improve the hand grip in people with muscle weakness due to multiple sclerosis (MS) and other conditions. The technology may be closer to entering people’s homes now that the startup has secured support…
FDA Approves Plegridy as Intramuscular Injection for Relapsing MS A common patient complaint about Plegridy has been that its subcutaneous injection procedure results in injection site reactions. This new formulation is delivered into the muscle, rather than under the skin. The needle is longer, but Biogen pharmaceuticals thinks the…
The recently launched BRAINTEASER project focuses on the use of artificial intelligence (AI) technology to improve the care of patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). An initiative of a European consortium, BRAINTEASER could benefit patients, caregivers, and clinicians by enhancing the ability to predict,…
A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The platform was described in the study “CogniSoft: A Platform for the Automation of Cognitive Assessment and Rehabilitation of Multiple Sclerosis,” published in the journal Computers. Cognitive impairment…
The Israeli Innovation Authority has awarded Owlytics Healthcare a $1.3-million grant to support the company’s development of wearable artificial intelligence (AI) technology that has the potential to improve multiple sclerosis (MS) therapies and better evaluate treatment efficacy in clinical studies. The device would be able to continuously…
Researchers developed a way of using machine learning to identify those cells most important for a given function or task, such as movement, and for evaluating how they respond to potentially restorative treatments. Using Augur, as this method is called, the team was able to identify the neural circuits in…
The Australian Government’s Medical Research Future Fund (MRFF) has awarded AU$7.1 million (about $4.95 million) to support two projects focused on harnessing the power of artificial intelligence (AI) and machine learning to develop new ways of diagnosing and treating multiple sclerosis (MS) and mental health disorders in young people.
Belong.Life has launched a free and anonymous social network app to offer support for people with multiple sclerosis (MS), their caregivers, and healthcare professionals. The app is called BelongMS and is now available…
A number of websites are currently offering online coronavirus screening. These aren’t a full-scale test. The online sites read symptoms that you enter and then use artificial intelligence to determine how likely it is that you’re positive for the virus. But there’s a bit of a problem. An investigation by…
CorTechs Labs presented new data indicating that machine learning models based on magnetic resonance imaging (MRI) of the brain may aid in the early diagnosis of multiple sclerosis (MS). Company representatives, joined by other experts, also released updated recommendations for a standardized…
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for QyScore, a cloud-based imaging software for the automated quantification of key magnetic resonance imaging (MRI) markers of central nervous system (CNS) disease. MRI is an important tool for diagnosing multiple sclerosis and other CNS disorders. By…
Combining data science, artificial intelligence (AI), and machine learning to better identify patterns that may underlie the cause or causes of multiple sclerosis (MS) is the focus of a novel partnership. Despite numerous advances in MS research and treatments, what causes the disease is still unknown. “Given the complexity…
TD Bank Group has donated $1 million to the Multiple Sclerosis (MS) Society of Canada to support research projects aiming to use artificial intelligence to create tools enabling better use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients. MS Society will channel these funds into its Acts of Greatness campaign,…
A new app might make it easier for healthcare providers to assess cognitive function in people with multiple sclerosis (MS). The app was described in the study, “iCAMS: Assessing the Reliability of a BICAMS Tablet Application,” published in the International Journal of MS…
DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making What’s the best way to attack multiple sclerosis when it’s first diagnosed? Do you hit it hard and fast using the most effective disease-modifying therapy (DMT), or do you start with a lower efficacy DMT and slowly ramp up?…
A new artificial intelligence (AI)-based model is better than conventional methods for detecting brain changes in response to treatment with Tysabri (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS), a study reports. The study, “High-dimensional detection of imaging response to treatment in multiple sclerosis,” was published in…
A new clinical application prototype that uses machine learning to help physicians predict the best treatment options for patients with multiple sclerosis (MS) will be unveiled at the American Academy of Neurology’s 2019 annual meeting May 4–10, in Philadelphia, Pennsylvania. The prototype is called PIN Population Data Platform. It has been…
A study suggests that it may be possible to create synthetic speech based on recordings of brain activity in people with irreversible speech loss due to neurological ills, such as multiple sclerosis (MS), Parkinson’s, or stroke. The system uses tiny electrodes implanted on the surface of the brain that directly records…
Artificial intelligence can help reduce the amount of gadolinium used as a contrast agent in MRI (magnetic resonance imaging) scans, preventing the agent’s potential toxicity when accumulated in body tissue, including the brain and bones, each time it is used, researchers suggest. The finding is of particular importance for…
Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study
Results from a first-in-human study assessing the safety and early activity of PRN2246Â confirmed that the oral compound can reach into the brain and spinal cord. This finding adds new evidence that PRN2246 has the potential to target the immune cells that drive the inflammatory process involved in multiple sclerosis…
IQuity, a data analytics company, announced the launch of an analytics platform that uses machine learning to predict, identify, and monitor chronic disease within large populations of patients, including multiple sclerosis (MS). The platform was validated using a pilot study that assessed the healthcare claims of 20 million people…
In a new study, researchers based at the Imperial College, London will follow in unprecedented detail the events and experiences in lives of people with multiple sclerosis (MS) in order to improve evaluation protocols for MS treatments. MS is estimated to afflict more than two million people globally, more…